Infection safety of blood components is still a major topic in transfusion medicine. In the last decades the worldwide routine implementation of nucleic acid amplification techniques (NAT) has led to the prevention of several transfusion-transmitted infections. The main emphasis was placed on the Big Three: hepatitis C virus (HCV), human immunodeficiency virus (HIV), and hepatitis B virus (HBV). In addition, further targets were tested (e.g. hepatitis A virus (HAV), parvovirus B19 (B19V)) due to the requirements of the plasma fractionation industry or, in the case of WestNile virus (WNV) or hepatitis E virus (HEV), due to new risk assessments. In 1997, the German blood centers were global forerunners in the introduction of viral NAT screening [1] . Despite the cost and logistical challenges to blood banks, NAT testing was implemented in a voluntary, later mandated manner. The molecular genetic techniques evolved from manually to fully automated performed steps, including sample pooling, nucleic acid extraction, amplification of specific targets, and detection. Today, terms like hands-on time, walk-away time, time to result, and high throughput are in the front line when thinking about NAT screening in blood centers. At present, previously known problems with PCR contamination using open systems have almost become unknown in practice. Standardization of NAT enables comparison and rating of NAT assays regarding specificity, sensitivity, and robustness [2] . Today, the focus is set on quality assurance, maximal automation, and consolidation regarding personal and material resources.
In the present issue of Transfusion Medicine and Hemotherapy, two blood screening platforms are presented that fulfil the requirements of modern NAT screening. Heim [3] reports the results of the evaluation of the Procleix Ultrio Elite Assay and the Panther system (Grifols) for individual NAT screening of blood, hematopoietic stem cell, tissue and organ donors. Furthermore, other highly automated NAT testing systems, like the autoX 2.0 (GFE Blut), are used for high-throughput blood donation testing. national migration and travel from Latin America to Europe. Central and South America are endemic regions for several tropical diseases, e.g. the Chagas disease, a zoonosis also known as American trypanosomiasis, which is a potentially life-threatening infection caused by the hemoflagellate protozoan Trypanosoma cruzi. In the absence of its vector, blood-sucking triatomine bugs, one of the potential modes of transmission of Chagas disease in non-endemic regions is through blood and blood products [8] . Experience with selective testing of at-risk blood donors for Trypanosoma cruzi and Plasmodium spp. in Switzerland is presented by Niederhauser et al. [9] .
Altogether, this issue of Transfusion Medicine and Hemotherapy provides an insight into new developments in NAT screening of blood donations, focusing on novel targets and full automation of testing, leading to the further improvement of blood safety.
